KCNJ10 and myeloid sarcoma: They confirmed the presence of anti-Kir4.1 antibodies in patients with MS, but at a much lower prevalence than was reported by Srivastava et al. Nerrant et al. also developed an ELISA, with the peptide Kir4.183–120 corresponding to the first extracellular loop of Kir4.1 containing target epitopes for anti-Kir4.1 antibodies [45].